SM-88 efficacy and safety in metastatic breast cancers.

Xinhua Zhu; Marcus Smith Noel; Patricia Zawisny; Zachary Gostout; Douglas Decorato; Gerald H. Sokol; Maria Loushin; Giuseppe Del Priore

doi:10.1200/JCO.2018.36.15_SUPPL.E13100

SM-88 efficacy and safety in metastatic breast cancers.

Xinhua Zhu
, Marcus Smith Noel
, Patricia Zawisny
, Zachary Gostout
, Douglas Decorato
, Gerald H. Sokol
, Maria Loushin
, Giuseppe Del Priore

Monter Cancer Center of North Shore - LIJ Health, Lake Success, NY;
Strong Memorial Hospital
QRI, New York, NY;
Tyme Technologies, Inc., New York, NY;
East River Medical Imaging, NY, NY;
Florida Cancer Institute New Hope, Hudson, FL;
Quality Research and Invention LLC, New York, NY;
Morehouse School of Medicine

Research output: Contribution to journal › Article › peer-review

Original language	American English
Journal	Journal of Clinical Oncology
Volume	36
DOIs	https://doi.org/10.1200/JCO.2018.36.15_SUPPL.E13100
State	Published - Jun 1 2018
Externally published	Yes

Disciplines

Medicine and Health Sciences
Oncology

Access to Document

10.1200/JCO.2018.36.15_SUPPL.E13100License: Unspecified

Cite this

@article{6e75996edb124a2d9966847ceb2c8452,

title = "SM-88 efficacy and safety in metastatic breast cancers.",

author = "Xinhua Zhu and Noel, \{Marcus Smith\} and Patricia Zawisny and Zachary Gostout and Douglas Decorato and Sokol, \{Gerald H.\} and Maria Loushin and \{Del Priore\}, Giuseppe",

note = "e13100 Background: SM-88 is a relatively non-toxic novel combination therapy (dysfunctional tyrosine, CYP3a4 inducer, mTOR inhibitor and oxidative stress catalyst) that has demonstrated efficacy in breast and other metastatic cancers. Early testing of SM-88 therapy with over 100 subjects has shown a potential efficacy signal, including RECIST responses in 13 different cancer types (JCO 2013, e22095), while maintaining a manageable toxicity profile (no grade 3-5 drug-related AEs).",

year = "2018",

month = jun,

day = "1",

doi = "10.1200/JCO.2018.36.15\_SUPPL.E13100",

language = "American English",

volume = "36",

journal = "Journal of Clinical Oncology",

}

TY - JOUR

T1 - SM-88 efficacy and safety in metastatic breast cancers.

AU - Zhu, Xinhua

AU - Noel, Marcus Smith

AU - Zawisny, Patricia

AU - Gostout, Zachary

AU - Decorato, Douglas

AU - Sokol, Gerald H.

AU - Loushin, Maria

AU - Del Priore, Giuseppe

N1 - e13100 Background: SM-88 is a relatively non-toxic novel combination therapy (dysfunctional tyrosine, CYP3a4 inducer, mTOR inhibitor and oxidative stress catalyst) that has demonstrated efficacy in breast and other metastatic cancers. Early testing of SM-88 therapy with over 100 subjects has shown a potential efficacy signal, including RECIST responses in 13 different cancer types (JCO 2013, e22095), while maintaining a manageable toxicity profile (no grade 3-5 drug-related AEs).

PY - 2018/6/1

Y1 - 2018/6/1

UR - https://ascopubs.org/doi/abs/10.1200/JCO.2018.36.15_suppl.e13100

U2 - 10.1200/JCO.2018.36.15_SUPPL.E13100

DO - 10.1200/JCO.2018.36.15_SUPPL.E13100

M3 - Article

VL - 36

JO - Journal of Clinical Oncology

JF - Journal of Clinical Oncology

ER -

SM-88 efficacy and safety in metastatic breast cancers.

Disciplines

Access to Document

Other files and links

Cite this